🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 100 of 116

  1. MLN4924

    Takeda

    Acute Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  2. MLN4924

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  3. MLN4924

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  4. MLN7243

    Takeda

    Advanced Malignant Solid Tumors

    phase 1 small molecule terminated

    1 trial

  5. MNPR-101-DFO*-89Zr

    Monopar Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  6. MNPR-101-PCTA-177Lu

    Monopar Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  7. MPT0B640

    INTENSITY THERAPEUTICS, INC.

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  8. MRG007

    ArriVent BioPharma

    Locally Advanced or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

  9. MRx0518

    4D Molecular Therapeutics

    Pancreatic Cancer

    phase 1 small molecule terminated

    1 trial

  10. MRx0518 Capsules

    4D Molecular Therapeutics

    Melanoma

    phase 1 small molecule active

    1 trial

  11. MSC2156119J

    Merck KGaA, Darmstadt, Germany

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  12. MT-401-OTS

    Marker Therapeutics

    Acute Myeloid Leukemia, in Relapse

    phase 1 small molecule active

    1 trial

  13. MT-601

    Marker Therapeutics

    Non-Hodgkin Lymphoma, Adult

    phase 1 small molecule active

    1 trial

  14. MT-601 dose 200 million cells

    Marker Therapeutics

    Pancreas Cancer

    phase 1 small molecule active

    1 trial

  15. MTL-CEBPA

    Hospital Authority, Hong Kong

    Advanced Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  16. MYCOPHENOLATE MOFETIL, INFLIXIMAB, Rilvegostomig, Rilvegostomig, volrustomig, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., Datopotamab deruxtecan, AZD7789

    AstraZeneca AB

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 1 small molecule active

    1 trial

  17. Mammaglobin-A DNA Vaccine

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 1 mab active

    1 trial

  18. Marijuana via vape device

    BRIGHT MINDS BIOSCIENCES INC.

    Cigarette Smoking-Related Carcinoma

    phase 1 small molecule active

    1 trial

  19. Master Protocol of Sotorasib (AMG 510) in Subjects with Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)

    Amgen

    Advanced Solid Tumors Kirsten Rat Sarcoma (KRAS) pG12C Mutation

    phase 1 other active

    1 trial

  20. Metabolically Armed CD19 CAR-T cells

    Anhui Provincial Hospital

    Acute Lymphoblastic Leukemia

    phase 1 small molecule active

    1 trial

  21. Methylene Blue (50 mg/10ml)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Cancer

    phase 1 small molecule active

    1 trial

  22. Mevrometostat Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

    Pfizer Australia Pty Ltd

    Castration Resistant Prostate Cancer (CRPC), Follicular Lymphoma (FL), Small Cell Lung Cancer (SCLC), Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 1 other active

    1 trial

  23. Midazolam

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule completed

    1 trial

  24. Midazolam

    Takeda

    Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors

    phase 1 small molecule completed

    1 trial

  25. Mifepristone and Eribulin in combination

    CORCEPT THERAPEUTICS INC

    Breast Cancer

    phase 1 small molecule completed

    1 trial

  26. Minnelide™Capsules

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  27. Mobocertinib

    Takeda

    Non-Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  28. Molecular imaging with FAPI for diagnosing the CSM4 colorectal cancer subtype

    Disc Medicine

    Colorectal cancer, liver metastases

    phase 1 other active

    1 trial

  29. NKTR-102

    Nektar Therapeutics UK Limited

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  30. NKTR-214

    Nektar Therapeutics UK Limited

    Advanced Cancer

    phase 1 mab completed

    1 trial

  31. NKTR-214 (Cohort A)

    INOVIO PHARMACEUTICALS, INC.

    Metastatic Castration-resistant Prostate Cancer

    phase 1 small molecule completed

    1 trial

  32. NM1F Injection

    TG THERAPEUTICS, INC.

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  33. NP-G2-044

    BRIGHT MINDS BIOSCIENCES INC.

    Breast Cancer

    phase 1 small molecule completed

    1 trial

  34. NX-1607

    Nurix Therapeutics

    Ovarian Cancer, Epithelial

    phase 1 small molecule active

    1 trial

  35. NX-2127

    Nurix Therapeutics

    Chronic Lymphocytic Leukemia (CLL)

    phase 1 small molecule active

    1 trial

  36. NXP800 in subjects with Ovarian Cancer

    Lacuna Pharma Pty Ltd

    Platinum-resistant, ARID1a-mutated ovarian, fallopian tube and primary peritoneal carcinoma

    phase 1 other active

    1 trial

  37. NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）

    Chongqing Precision Biotech Co., Ltd

    Bone Sarcoma

    phase 1 mab active

    1 trial

  38. Navitoclax

    AbbVie

    Acute Lymphoblastic Leukemia (ALL)

    phase 1 small molecule completed

    1 trial

  39. NeoTISLEGA - A phase Ib trial evaluating the safety and activity of neoadjuvant combination of tislelizumab plus FLOT for resectable esophagogastric adenocarcinoma

    The George Institute

    resectable esophagogastric adenocarcinoma

    phase 1 other active

    1 trial

  40. Neoadjuvant chemotherapy

    Hospital Authority, Hong Kong

    Squamous Cell Carcinoma of Oral Cavity

    phase 1 small molecule completed

    1 trial

  41. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Advanced Malignant Solid Tumors

    phase 1 small molecule completed

    3 trials

  42. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Neoplasms

    phase 1 small molecule completed

    1 trial

  43. Neratinib 160 mg

    PUMA BIOTECHNOLOGY, INC.

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  44. Neratinib Pill

    PUMA BIOTECHNOLOGY, INC.

    Gastric Cancer

    phase 1 small molecule active

    1 trial

  45. Nimotuzumab

    Biotech Pharmaceutical Co.,

    Solid Tumors

    phase 1 small molecule active

    1 trial

  46. Nimotuzumab and chemotherapy

    Biotech Pharmaceutical Co.,

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  47. Niraparib

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  48. Nivolumab

    Bristol-Myers Squibb

    Melanoma

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.